NURO

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Neurometrix Inc.

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.
CEO
Shai Gozani
Employees
20
Headquarters

1000 Winter St
Waltham, Massachusetts 02451-1436
Phone: 17818909989
www.neurometrix.com

News

Study shows NeuroMetrix Inc''s DPNCheck effective for DNP diagnosis
Mar 14, 2024 15:30pm

https://www.investing.com/news/stock-market-news/study-shows-neurometrix-incs-dpncheck-effective-for-dnp-diagnosis-93CH-3338344


Source:Investing.com
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
Mar 13, 2024 13:00pm

NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.


Source:GlobeNewswire
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell Fibromyalgia
Mar 13, 2024 13:00pm

WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
Mar 12, 2024 12:02pm

NURO stock price has declined 99% since its IPOGozani has received compensation of over $10 million since the IPOGozani was charged by the FTC for various wrongdoings at NUROGozani apparently perso…


Source:Finanz Nachrichten
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired | NURO Stock News
Mar 12, 2024 12:00pm

Echo Lake Capital urges Neurometrix, Inc. (NURO) to fire Chairman and CEO Shai Gozani due to the stock''s 99% decline since IPO, Gozani''s $10 million compensation, FTC charges, personal $4 million settlement, and dilution of NURO shares below net cash value.


Source:Stock Titan
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
Mar 12, 2024 12:00pm

NURO stock price has declined 99% since its IPOGozani has received compensation of over $10 million since the IPOGozani was charged by the FTC for various wrongdoings at NUROGozani apparently personally paid the FTC $4 million as part of a … Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
RS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
Mar 08, 2024 17:26pm

Stock trades significantly below its net cash per share.The board is arguably in breach of their fiduciary responsibility to protect shareholder value. Operating any capital raise at current price …


Source:Finanz Nachrichten
Chemotherapy Induced Peripheral Neuropathy Treatment Market Projected Strong Growth to $2.25 Billion by 2028 Amid Advancements in Cancer Treatment
Mar 07, 2024 00:00am


Source:Kwhen Finance
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
Mar 04, 2024 13:00pm

- Stock trades significantly below its net cash per share- Questions the Board''s ability and/or desire to create shareholder value- Notes tremendous destruction of shareholder value under company''s leadership- Sees no reason for company to remain … Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Earnings call: NeuroMetrix reports Q4 revenue drop, shifts focus
Feb 23, 2024 22:23pm

https://www.investing.com/news/stock-market-news/earnings-call-neurometrix-reports-q4-revenue-drop-shifts-focus-93CH-3313695


Source:Investing.com